Invention Grant
- Patent Title: Engineered aryl sulfate-dependent enzymes
-
Application No.: US17894932Application Date: 2022-08-24
-
Publication No.: US11767518B2Publication Date: 2023-09-26
- Inventor: Tarsis Gesteira Ferreira , Daniel H. Lajiness
- Applicant: OPTIMVIA, LLC
- Applicant Address: US OH Batavia
- Assignee: OPTIMVIA, LLC
- Current Assignee: OPTIMVIA, LLC
- Current Assignee Address: US OH Batavia
- Agency: Nesbitt IP LLC
- Agent Daniel H. Lajiness; Daniel F. Nesbitt
- The original application number of the division: US17376332 2021.07.15
- Main IPC: C12N9/10
- IPC: C12N9/10 ; C12N15/63 ; C12P19/64

Abstract:
The present invention provides several non-naturally occurring sulfotransferase enzymes that have been engineered to react with aryl sulfate compounds as sulfo group donors, instead of the natural substrate 3′-phosphoadenosine 5′-phosphosulfate (PAPS), and with heparosan-based polysaccharides, particularly heparan sulfate, as sulfo group acceptors. Each of the engineered sulfotransferase enzymes have a biological activity characterized by the position within the heparosan-based polysaccharide that receives the sulfo group, including glucosaminyl N-sulfotransferase activity, hexuronyl 2-O sulfotransferase activity, glucosaminyl 6-O sulfotransferase activity, or glucosaminyl 3-O sulfotransferase activity. Methods of using the engineered sulfotransferases to produce sulfated heparosan-based polysaccharides, including polysaccharides having anticoagulant activity, are also provided.
Public/Granted literature
- US20230051957A1 ENGINEERED ARYL SULFATE-DEPENDENT ENZYMES Public/Granted day:2023-02-16
Information query